Home > Blog

4 min read

Planning the Way Forward in Neurodegenerative Disease Studies

Clinical trials involving gene therapies for the treatment of Central Nervous System (CNS) indications are some of the more complex in the field of gene and cell therapy (G&CT) development. During the lockdown, the Food and Drug Administration (FDA)...

READ MORE

2 min read

Regulatory Guidance Monthly Review - May 2021

May 2021 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device...

READ MORE

2 min read

Regulatory Guidance Monthly Review - April 2021

April 2021 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE

2 min read

Regulatory Guidance Monthly Review - March 2021

March 2021 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE

3 min read

Harnessing Efficiencies in a Post-COVID World

The COVID-19 pandemic has accelerated the clinical trial communitys quest to streamline its data-driven processes in order to find new and better ways to gain flexibility and efficiency throughout the clinical development continuum.

READ MORE

2 min read

Regulatory Guidance Monthly Review - February 2021

February 2021 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE

1 min read

Regulatory Guidance Monthly Review - January 2021

January 2021 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE

1 min read

Regulatory Guidance Monthly Review - December 2020

December 2020 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE

3 min read

Adapting Human Connection in a Virtual World

How We Planned an International Meeting in a Pandemic

Looking back, 2020 has taught us all a few lessons we were not expecting to learn.

READ MORE

3 min read

Regulatory Guidance Monthly Review - November 2020

November 2020 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE